Skip to main content
SpringerLink
Log in

Cardiometabolic Syndrome

  • Chapter
Cardiorenal Syndrome

  • 1080 Accesses

Abstract

Cardiometabolic syndrome is a common condition that is increasing in prevalence in the USA and developing nations. Epidemiological studies indicate a strong association between cardiometabolic syndrome and subsequent risks for diabetes and cardiovascular events. Accumulating evidence suggests it may also be a risk factor for incident chronic kidney disease (CKD) and cardiovascular events in individuals with pre-existing CKD. In studies of nondiabetic individuals, cardiometabolic syndrome was associated with a 30–100% increased risk for incident CKD. Among individuals with advanced CKD, cardiometabolic syndrome was associated with >100% increased risk for cardiovascular events, but findings in individuals with earlier stages of CKD were not consistent. Furthermore, the clinical utility of this syndrome and, in particular, its role in risk prediction, remains uncertain. Whereas the syndrome appears to be of value in identifying nondiabetic individuals at risk for developing cardiovascular disease (CVD) and CKD, it is unclear whether the diagnosis of cardiometabolic syndrome carries specific therapeutic implications. At present, most guidelines recommend therapies targeted at lifestyle modification and treatment of individual risk factors, whereas the role of pharmacological therapies targeting insulin resistance needs further study

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 137:1595–1607

    Article  Google Scholar 

  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497

    Article  Google Scholar 

  3. Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752

    Article  PubMed  Google Scholar 

  4. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553

    Article  CAS  PubMed  Google Scholar 

  5. Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443

    Article  CAS  PubMed  Google Scholar 

  6. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23:469–480

    Article  CAS  PubMed  Google Scholar 

  7. Chen J, Muntner P, Hamm LL et al (2004) The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167–174

    PubMed  Google Scholar 

  8. Palaniappan L, Carnethon M, Fortmann SP (2003) Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 16:952–958

    Article  CAS  PubMed  Google Scholar 

  9. Hoehner CM, Greenlund KJ, Rith-Najarian S et al (2002) Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 13:1626–1634

    Article  CAS  PubMed  Google Scholar 

  10. Mykkanen L, Zaccaro DJ, Wagenknecht LE et al (1998) Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 47:793–800

    Article  CAS  PubMed  Google Scholar 

  11. Lucove J, Vupputuri S, Heiss G et al (2008) Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study. Am J Kidney Dis 51:21–28

    Article  CAS  PubMed  Google Scholar 

  12. Kurella M, Lo JC, Chertow GM (2005) Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16:2134–2140

    Article  PubMed  Google Scholar 

  13. Ninomiya T, Kiyohara Y, Kubo M et al (2006) Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 48:383–391

    Article  PubMed  Google Scholar 

  14. Ryu S, Chang Y, Woo HY et al (2009) Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am J Kidney Dis 53:59–69

    Article  CAS  PubMed  Google Scholar 

  15. Rashidi A, Ghanbarian A, Azizi F (2007) Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol 2:976–983

    Article  CAS  PubMed  Google Scholar 

  16. Kitiyakara C, Yamwong S, Cheepudomwit S et al (2007) The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 71:693–700

    Article  CAS  PubMed  Google Scholar 

  17. Lea J, Cheek D, Thornley-Brown D et al (2008) Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis 51(5):732–740

    Article  CAS  PubMed  Google Scholar 

  18. Luk AO, So WY, Ma RC et al (2008) Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 31:2357–2361

    Article  PubMed  Google Scholar 

  19. Bagby SP (2004) Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 15:2775–2791

    Article  PubMed  Google Scholar 

  20. Wahba IM, Mak RH (2007) Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2:550–562

    Article  CAS  PubMed  Google Scholar 

  21. Alexander MP, Patel TV, Farag YM et al (2009) Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis 53:751–759

    Article  CAS  PubMed  Google Scholar 

  22. Yoshida T, Kato K, Fujimaki T et al (2009) Association of a polymorphism of the apolipoprotein E gene with chronic kidney disease in Japanese individuals with metabolic syndrome. Genomics 93:221–226

    Article  CAS  PubMed  Google Scholar 

  23. Cirillo P, Sato W, Reungjui S et al (2006) Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol 17:S165–168

    Article  Google Scholar 

  24. Wannamethee SG, Shaper AG, Lennon L, Morris RW (2005) Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165:2644–2650

    Article  PubMed  Google Scholar 

  25. Shinohara K, Shoji T, Emoto M et al (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13:1894–1900

    Article  PubMed  Google Scholar 

  26. Johnson DW, Armstrong K, Campbell SB et al (2007) Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 12:391–398

    Article  CAS  Google Scholar 

  27. Courivaud C, Kazory A, Simula-Faivre D et al (2007) Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 83:1577–1581

    Article  PubMed  Google Scholar 

  28. Ramkumar N, Murtaugh MA, Cheung AK, Beddhu S (2007) Lack of synergistic effects of metabolic syndrome and plasma fibrinogen on coronary events and mortality in moderate CKD. Am J Kidney Dis 49:356–364

    Article  CAS  PubMed  Google Scholar 

  29. Klausen KP, Parving HH, Scharling H, Jensen JS (2007) The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med 262:470–478

    Article  CAS  PubMed  Google Scholar 

  30. Becker B, Kronenberg F, Kielstein JT et al (2005) Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16:1091–1098

    Article  CAS  PubMed  Google Scholar 

  31. Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289–2304

    Article  PubMed  Google Scholar 

  32. Stern MP, Williams K, González-Villalpando C et al (2004) Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diab Care 27(11):2676–2681

    Article  Google Scholar 

  33. McNeill AM, Rosamond WD, Girman CJ et al (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diab Care 28(2):385–390

    Article  Google Scholar 

  34. Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348(5):383–393

    Article  PubMed  Google Scholar 

  35. Orchard TJ, Temprosa M, Goldberg R et al (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Int Med 142(8):611–6199

    CAS  PubMed  Google Scholar 

  36. Chagnac A, Weinstein T, Herman M et al (2003) The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14:1480–1486

    Article  PubMed  Google Scholar 

  37. Cheung AK (2009) Is lipid control necessary in hemodialysis patients? Clin J Am Soc Nephrol 4:SS5–S101

    Article  Google Scholar 

  38. Strippoli GF, Navaneethan SD, Johnson DW et al (2008) Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336:645–651

    Article  CAS  PubMed  Google Scholar 

  39. Wanner C, Krane V, Marz W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248

    Article  CAS  PubMed  Google Scholar 

  40. Fellstrom BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407

    Article  CAS  PubMed  Google Scholar 

  41. Dagenais GR, Gerstein HC, Holman R et al (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31:1007–1014

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Stanford University School of Medicine and VA Palo Alto Health Care System, Geriatrics Research and Education Clinical Center, Palo Alto, CA, USA

    Manjula Kurella Tamura

  2. Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA, USA

    Tara I. Chang

Authors
  1. Manjula Kurella Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tara I. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

    Adel E. Berbari

  2. Clinica Medica Department of Clinical Medicine and Prevention, University of Milano-Bicocca San Gerardo Hospital, Monza, Milan, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Italia

About this chapter

Cite this chapter

Tamura, M.K., Chang, T.I. (2010). Cardiometabolic Syndrome. In: Berbari, A.E., Mancia, G. (eds) Cardiorenal Syndrome. Springer, Milano. https://doi.org/10.1007/978-88-470-1463-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1463-3_10

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1462-6

  • Online ISBN: 978-88-470-1463-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation